Cardinal Health, Inc.
Cardinal Health, Inc. provides health care products and services.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cardinal Health's stock, indicating potential growth despite current pricing.
Financial Health
Cardinal Health is generating steady revenue and cash flow, but faces challenges with profit margins.
Dividend
Cardinal Health's dividend yield of 1.36% is lower than many other stocks, making it less appealing for dividend-seeking investors. If you invested $1000 you would be paid $13.00 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CAH
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketWalgreens Restructuring Explained: Investment Shifts
Following its acquisition by Sycamore Partners, Walgreens has gone private and split into five companies. This theme explores the investment opportunities created by the newly independent healthcare and retail entities.
Published: September 2, 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: August 29, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Scale & Distribution
A wide distribution network underpins revenue through volume, but margins are typically thin so operational efficiency is essential.
Higher‑Margin Push
Growth in medical devices and services aims to lift margins, though execution risk and competitor response are important considerations.
Regulation & Cycles
Reimbursement trends, hospital spending cycles and regulatory changes can materially affect performance, and returns may vary over time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
